WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005032465) 3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/032465    International Application No.:    PCT/US2004/031675
Publication Date: 14.04.2005 International Filing Date: 27.09.2004
IPC:
A61K 31/4245 (2006.01), C07D 271/06 (2006.01)
Applicants: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US) (For All Designated States Except US).
DOHERTY, George, A. [US/US]; (US) (For US Only).
HALE, Jeffrey, J. [US/US]; (US) (For US Only).
LEGIEC, Irene, E. [US/US]; (US) (For US Only).
LYNCH, Christopher, L. [US/US]; (US) (For US Only).
TOTH, Leslie, M. [US/US]; (US) (For US Only)
Inventors: DOHERTY, George, A.; (US).
HALE, Jeffrey, J.; (US).
LEGIEC, Irene, E.; (US).
LYNCH, Christopher, L.; (US).
TOTH, Leslie, M.; (US)
Common
Representative:
MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US)
Priority Data:
60/507,622 01.10.2003 US
Title (EN) 3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS
(FR) 1,2,4-OXADIAZOLES SUBSTITUES 3,5-ARYLE, HETEROARYLE OU CYCLOALKYLE SERVANT D'AGONISTES DU RECEPTEUR S1P
Abstract: front page image
(EN)The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
(FR)L'invention concerne des composés représentés par la formule I ainsi que les sels pharmaceutiquement acceptables de ces composés. Lesdits composés servent au traitement de maladies et de troubles d'origine immunologique tels que les rejets de greffe de moelle osseuse, d'organes et de tissus. L'invention concerne également des compositions pharmaceutiques et des procédés d'utilisation de ces compositions.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)